Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Kalgi Mody, Josep M. Llovet

Journal of Clinical Oncology, 2020

University of California, Los Angeles, Los Angeles Medical Center, National Cancer Center Hospital East, Harvard University, Massachusetts General Hospital, Tisch Cancer Institute, Tisch Hospital, Sutter Health, California Pacific Medical Center, Kindai University, Toranomon Hospital, Kanazawa University, Centre Eugène Marquis, Regional Public Health Care Institution "City Hospital No. 5, Barnaul", Royal Free London NHS Foundation Trust, National Health Service, Eisai (Japan), Eisai (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Universitat de Barcelona, Biomedical Research Institute, Icahn School of Medicine at Mount Sinai

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with Journal of Clinical Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1154

Citations

View on Google Scholar

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Abstract

Journal Details

Join JournalsHub

Welcome Back